The Cancer Letter

Inside information on cancer research and drug development

Clinical

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Pfizer Inc. and Astellas Pharma Inc. announced the phase III PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy versus ADT alone in patients with non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer. 
Clinical Roundup

Blood test predicts prognosis for advanced prostate cancer, study finds

A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account